Physician profile
Amy Lynn Thomas
NPI 1497739882
$12,208.26
in general payments reported to CMS, 2019-2025
42 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $1,708 · 2021: $2,138 · 2022: $1,607 · 2023: $1,240 · 2024: $2,165 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,600.02 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,556.08 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,512.11 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $1,103.11 | 2019-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.22 | 2019-2025 | Jardiance, Synjardy |
| Allergan, INC. | $609.43 | 2019-2020 | |
| Pfizer INC. | $534.06 | 2020-2025 | |
| Si-Bone, INC. | $405.33 | 2019-2024 | |
| Amarin Pharma, INC. | $382.11 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $332.23 | 2022-2025 | Quviviq, Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $312.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $280.92 | 2019-2022 | |
| Glaxosmithkline, LLC. | $261.27 | 2019-2024 | Arexvy, Shingrix, Pediarix |
| Merck Sharp & Dohme LLC | $256.97 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Biohaven Pharmaceuticals, INC. | $241.85 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.